Here’s what you should know.
1. The prescription is used to treat gastroparesis in patients with type 1 and type 2 diabetes.
2. The trial evaluated the effects of relamorelin on key signs and symptoms of gastroparesis.
3. The trial was performed in a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of dosing requirements.
4. Relamorelin was found to be safe and well-tolerated. There were some dose-related adverse events associated with it including the worsening of glycemic control in some patients.
5. Allergan will pay $200 million to Rhythm Holdings at the deal’s closing. Rhythm will also receive a contingent payment over the commercial sale of relamorelin.
More articles on GI/endoscopy:
Nonalcoholic fatty liver disease associated with $103B in annual medical costs: 3 study insights
https://www.beckersasc.com/gastroenterology-and-endoscopy/nonalcoholic-fatty-liver-disease-associated-with-103b-in-annual-medical-costs-3-study-insights.html
AGA launches patient education platform for IBD, pregnancy concerns: 3 notes
https://www.beckersasc.com/gastroenterology-and-endoscopy/aga-launches-patient-education-platform-for-ibd-pregnancy-concerns-3-notes.html
GI leader to know: Dr. R. David Shepard of Florida Medical Clinic
https://www.beckersasc.com/gastroenterology-and-endoscopy/gi-leader-to-know-dr-r-david-shepard-of-florida-medical-clinic.html
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
